MUC1 and non-small cell lung carcinoma: One of the major phase III clinical trials used TG4010, a modified vaccinia Ankara vector expressing MUC1 and interleukin-2, in combination with chemotherapeutic drugs or placebo in 222 non-small cell lung cancer (NSCLC) patients [114].